诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

盘后交易 12-26 18:03:08 EST

87.65

+0.28

+0.32%

盘后87.74

+0.09+0.10%

18:01 EST

最高88.06	最低86.87	成交量628.93万
今开87.17	昨收87.37	日振幅1.36%
总市值3,878亿	流通市值2,774亿	总股本44.24亿
成交额5.51亿	换手率0.20%	流通股本31.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":87.65,"timestamp":1735246800000,"preClose":87.37,"halted":0,"volume":6289289,"hourTrading":{"tag":"盘后","latestPrice":87.74,"preClose":87.65,"latestTime":"18:01 EST","volume":236999,"amount":20774089.280245,"timestamp":1735254102252},"delay":0,"floatShares":3164393375,"shares":4424320356,"eps":3.170878,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.28,"latestTime":"12-26 18:03:08 EST","open":87.17,"high":88.06,"low":86.87,"amount":551031904.80426,"amplitude":0.01362,"askPrice":88,"askSize":40,"bidPrice":87.73,"bidSize":50,"shortable":3,"etf":0,"ttmEps":3.170878,"exchange":"NYSE","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1735261200000},"adr":1,"listingDate":363499200000,"adjPreClose":87.37,"adrRate":1,"dividendRate":0.016623,"preHourTrading":{"tag":"盘前","latestPrice":87.1642,"preClose":87.37,"latestTime":"09:29 EST","volume":16535,"amount":1443187.6972999999,"timestamp":1735223394088},"postHourTrading":{"tag":"盘后","latestPrice":87.74,"preClose":87.65,"latestTime":"18:01 EST","volume":236999,"amount":20774089.280245,"timestamp":1735254102252},"volumeRatio":0.362948,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1737090000000,"strike":"105.0","timestamp":1735242604743,"price":17.100000381469727,"volume":7060,"amount":12072600,"type":"+"},{"symbol":"NVO","call":false,"expireDate":1737090000000,"strike":"110.0","timestamp":1735242604743,"price":22.100000381469727,"volume":7060,"amount":15602600,"type":"+"}]},"impliedVol":0.3387,"impliedVolPercentile":0.3889},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2494685084","title":"“诺礼”减肥神药主流化背后，适用性、医保等新挑战悄然而至","url":"https://stock-news.laohu8.com/highlight/detail?id=2494685084","media":"智通财经","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494685084?lang=zh_cn&edition=full","pubTime":"2024-12-26 20:35","pubTimestamp":1735216506,"startTime":"0","endTime":"0","summary":"为此，一个由肥胖专家组成的国际委员会将在2025年初发布一份中期报告，列出诊断“临床”肥胖的标准，以及超重在哪些方面会导致或增加其他健康问题的风险。通常情况下，一旦BMI降至一定水平以下，患者就会失去GLP-1的保险。但令人担忧的是，这些药物不仅会导致脂肪和肌肉的减少，还会影响营养的摄入。所有这些都必须考虑到患者的减肥过程。因此，数据最终将成为最好的指南。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1229757.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“诺礼”减肥神药主流化背后，适用性、医保等新挑战悄然而至","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVO","LLY"],"gpt_icon":1},{"id":"2494592813","title":"诺和诺德又遭打击：马斯克晒瘦身照，称用礼来减肥药比司美格鲁肽有效","url":"https://stock-news.laohu8.com/highlight/detail?id=2494592813","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494592813?lang=zh_cn&edition=full","pubTime":"2024-12-27 06:04","pubTimestamp":1735250692,"startTime":"0","endTime":"0","summary":"马斯克圣诞节晒照自称是Ozempic圣诞老人，又澄清说不是司美格鲁肽那个药名Ozempic，是礼来的竞品Mounjaro，还说“高剂量”的Ozempic药物会让他放屁和打嗝，“Mounjaro 似乎副作用更少，而且更有效。”","market":"hk","thumbnail":"https://wpimg-wscn.awtmt.com/0f594539-828c-48f0-a085-7413061fedd6.jpeg","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/0f594539-828c-48f0-a085-7413061fedd6.jpeg"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3737863","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3737863","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["IE00BJJMRZ35.SGD","IE00BKVL7J92.USD","SG9999014898.SGD","LU0820562030.AUD","BK4548","LU0471298777.SGD","LU1035775433.USD","SG9999018857.SGD","IE0009355771.USD","LU1983299246.USD","TSYW.SI","LU2237443978.SGD","LU1551013342.USD","LU2237443465.HKD","LU1280957306.USD","LLY","LU1868836591.USD","LU0820561818.USD","LU0689472784.USD","LU1720051108.HKD","LU0198837287.USD","LU0708995401.HKD","LU0056508442.USD","NVO","SG9999015945.SGD","LU2213496289.HKD","LU2264538146.SGD","TSLA","LU2237443382.USD","LU1093756325.SGD","LU1917777945.USD","LU0061475181.USD","LU1861220033.SGD","SGXZ99366536.SGD","LU2602419157.SGD","BK4581","BK4551","LU0096364046.USD","LU1551013425.SGD","LU0417517546.SGD","IE00B4R5TH58.HKD","GB00BDT5M118.USD","LU0006306889.USD","LU2023250504.SGD","IE00B1BXHZ80.USD","LU0823414478.USD","LU1868837300.USD","SGXZ81514606.USD","IE00BK4W5L77.USD"],"gpt_icon":1},{"id":"2494789989","title":"马斯克曝转用礼来减肥药：效果优于诺和诺德竞品，副作用更少","url":"https://stock-news.laohu8.com/highlight/detail?id=2494789989","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494789989?lang=zh_cn&edition=full","pubTime":"2024-12-27 02:54","pubTimestamp":1735239273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4550","BK4599","LU0820561818.USD","LU0234572021.USD","LU1914381329.SGD","LU1917777945.USD","LU0114720955.EUR","LU2361044949.HKD","LU0882574139.USD","TSYW.SI","IE00BK4W5L77.USD","LU2237443895.HKD","LU1720051017.SGD","LU1629891620.HKD","LU1814569148.SGD","BK4533","LU0320765059.SGD","LU0106261372.USD","LU1861559042.SGD","IE0004445239.USD","BK4511","LU0943347566.SGD","LU1983299246.USD","LU0082616367.USD","LU0456855351.SGD","NVO","LU0109391861.USD","LU0820562030.AUD","LU0094547139.USD","LU2360106780.USD","LU2756315664.SGD","LU2360106947.USD","BK4099","DXYZ","SG9999001176.USD","IE0002141913.USD","BK4527","LU0256863811.USD","LU2237438978.USD","LU1127390331.HKD","LLY","LU1868836914.USD","TSLA","IE00BWXC8680.SGD","SG9999014906.USD","LU0122379950.USD","LU1712237335.SGD","LU0689472784.USD","LU1868837300.USD","BK4574"],"gpt_icon":0},{"id":"2494755896","title":"马斯克自曝转用礼来减肥药：效果优于诺和诺德竞品，副作用更少","url":"https://stock-news.laohu8.com/highlight/detail?id=2494755896","media":"媒体滚动","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494755896?lang=zh_cn&edition=full","pubTime":"2024-12-27 02:34","pubTimestamp":1735238069,"startTime":"0","endTime":"0","summary":"财联社12月27日讯 世界首富埃隆·马斯克周三在社交媒体平台X上透露，他正在使用礼来公司的 Mounjaro来减肥。　　马斯克在X上发布了一张他打扮成圣诞老人的照片，照片中他站在一棵圣诞树旁，并配文“Ozempic圣诞老人”。　　马斯克随后在多条帖子中证实自己确实在使用类似Ozempic的药物来减重。　　作为减肥药市场的双子星，礼来与诺和诺德产品效果的对比备受关注。今年7月公布的一项研究显示，礼来的Mounjaro能比诺和诺德的Ozempic更快、更有效地减肥。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2024-12-27/doc-ineavsec0744565.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU1868837136.USD","LU2237443622.USD","LU0882574139.USD","LU1548497426.USD","IE00B4R5TH58.HKD","IE00BWXC8680.SGD","LU1868836914.USD","LU1127390331.HKD","LU1551013342.USD","LU0823411888.USD","SG9999017495.SGD","LU0471298777.SGD","LU0385154629.USD","NVO","LLY","BK4534","LU0122379950.USD","LU0114720955.EUR","LU2106854487.HKD","SG9999014880.SGD","LU2237438978.USD","SGXZ81514606.USD","LU2326559502.SGD","IE00B2B36J28.USD","GB00BDT5M118.USD","LU2087621335.USD","LU0820561818.USD","TSLA","BK4585","LU2237443382.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","SGXZ57979304.SGD","LU0708995401.HKD","BK4516","IE00BJLML261.HKD","LU0640476718.USD","LU2491050071.SGD","TSYW.SI","LU1280957306.USD","LU0109391861.USD","SG9999014914.USD","LU2461242641.AUD","LU2361045086.USD","BK4555","BK4533","LU1720051017.SGD","LU1366192091.USD","LU2357305700.SGD"],"gpt_icon":1},{"id":"2494171003","title":"国家医保局声明从未授权任何社会人员激活“电子医保卡”；诺和诺德突破性血友病疗法获FDA批准 | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2494171003","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494171003?lang=zh_cn&edition=full","pubTime":"2024-12-26 07:48","pubTimestamp":1735170522,"startTime":"0","endTime":"0","summary":"｜ 2024年12月26日 星期四 ｜NO.1国家医保局：从未授权任何社会人员激活“电子医保卡”国家医保局发布声明称，从未授权任何社会人员开展群众的“电子医保卡”激活工作。请广大群众提高警惕，不要轻信陌生人以激活电子医保卡名义收集个人信息。NO.2诺和诺德突破性血友病疗法获FDA批准诺和诺德公司日前宣布，美国FDA已批准Alhemo皮下注射剂作为一种每日一次的预防性治疗，用于预防或减少12岁及以上血友病A或B成人和儿童患者的出血频率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226074904a2099f3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226074904a2099f3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756325.SGD","LU1093756168.USD","BK4599","NVO","LU0154236417.USD","BK4588","IE00BZ1G4Q59.USD","BK4532","BK4585","BK4007","IE00BKVL7J92.USD"],"gpt_icon":1},{"id":"2494882362","title":"医药行业研究：诺和诺德血友病疗法ALHEMO获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2494882362","media":"太平洋证券股份...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494882362?lang=zh_cn&edition=full","pubTime":"2024-12-26 00:00","pubTimestamp":1735142400,"startTime":"0","endTime":"0","summary":"行业要闻：近日，诺和诺德宣布，美国FDA 已批准Alhemo皮下注射剂作为一种每日一次的预防性治疗，用于预防或减少12 岁及以上血友病A 或B 成人和儿童患者的出血频率。该药通过阻断TFPI 增强凝血酶的生成，从而弥补其他凝血因子的缺失或不足。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226131142984fbea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241226131142984fbea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","BK4588","NVO","LU1093756325.SGD","BK4007","IE00BKVL7J92.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4532","BK4585"],"gpt_icon":1},{"id":"2494409630","title":"暴跌20%！市值蒸发600亿！诺和诺德又输了一局？","url":"https://stock-news.laohu8.com/highlight/detail?id=2494409630","media":"生物科技馆","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494409630?lang=zh_cn&edition=full","pubTime":"2024-12-25 11:31","pubTimestamp":1735097496,"startTime":"0","endTime":"0","summary":"市值蒸发数百亿，竞争对手股价上涨受CagriSema临床试验结果未达预期的影响，诺和诺德的股价在周五早盘下跌约19%，市值蒸发了数百亿美元。而在这场竞赛中，诺和诺德的CagriSema虽然未能完全超越预期，但仍然显示出了一定的减肥效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225114240ab9170c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225114240ab9170c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","IE00BZ1G4Q59.USD","BK4007","BK4599","LU1093756325.SGD","LU1093756168.USD","IE00BKVL7J92.USD","NVO","BK4585","BK4588","LU0154236417.USD"],"gpt_icon":1},{"id":"2494166067","title":"机构：诺和诺德上周五净资金流入飙升32倍 因减肥药数据不及预期提供进场机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2494166067","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2494166067?lang=zh_cn&edition=full","pubTime":"2024-12-25 10:06","pubTimestamp":1735092418,"startTime":"0","endTime":"0","summary":"投资研究公司Vanda Research数据显示，诺和诺德上周五单日净资金流入飙升32倍，从前一天的49万美元攀升至1560万美元，因为其令人失望的减肥药数据提供罕见的逢低进场机会。诺和诺德公布的数据表明，实验药物CagriSema只帮助患者减轻22.7%的体重，不及预期的25%。诺和诺德美股上周五盘中一度暴跌 21%，至81.5美元，为2023年8月以来的最低水平。上周五的散户资金流动可能为机构投资人提供了退出管道。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"01ebf9578c8e8793ab1eb4c6159ee2ba","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/12/25100646783005.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4588","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4532","LU1093756168.USD","IE00BKVL7J92.USD","BK4599","BK4007","NVO","BK4585","LU1093756325.SGD"],"gpt_icon":0},{"id":"2493082124","title":"减肥药数据令人失望，散户投资者买入诺和（Novo）跌停股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2493082124","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493082124?lang=zh_cn&edition=full","pubTime":"2024-12-24 22:34","pubTimestamp":1735050892,"startTime":"0","endTime":"0","summary":"路透12月24日 - 据Vanda Research公司称，美国散户投资者流入诺和诺德NVO.N的资金周五激增32倍，因为这家丹麦制药商的肥胖症药物数据弱于预期，提供了一个难得的逢低买入机会。每日净流量从前一天的49万美元攀升至1560万美元，此前人们热切期待的数据 ，显示诺和诺德的实验性药物CagriSema帮助患者减轻了22.7%的体重，低于预期的25%。\"散户投资者喜欢逢低买入，尤其是热门股票，直到这种做法不再奏效为止。诺和诺德股价周五下跌 27%，市值缩水超过 1,000 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"01ebf9578c8e8793ab1eb4c6159ee2ba","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241224:nL4S3NP0PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["3NVD.UK","LU2505996681.GBP","NVDY","SG9999001176.SGD","IE00BYXW3230.USD","HK0000320264.USD","LU1066053197.SGD","LU2213496289.HKD","NVDD","LU1084165304.USD","NVDU","LLY","LU1093756168.USD","LU1721428933.USD","LU0889565833.HKD","NVD2.UK","NVDX","NVIW.SI","LU0289739343.SGD","LU0823421416.USD","LU1551013425.SGD","NVDA","NVD3.UK","2NVD.UK","IE00BJT1NW94.SGD","LU2089984988.USD","IE00B19Z9505.USD","HK0000306685.HKD","LU1935043536.SGD","SNVD.UK","NVDS","NVO","LU0061474705.USD","LU2420271590.USD","TSLA","LU1983260115.SGD","TSYW.SI","LU2360032135.SGD","LU1951198990.SGD","NVD","NVDS.UK","LU0642271901.SGD","LU0053666078.USD","SG9999014906.USD","LU1066051498.USD","IE0009356076.USD","IE00BMPRXR70.SGD","IE00B4R5TH58.HKD","LU1116320901.HKD"],"gpt_icon":1},{"id":"2493177805","title":"诺和诺德(NVO.US)Alhemo皮下注射剂获FDA批准 预防或减少12岁及以上血友病患者出血频率","url":"https://stock-news.laohu8.com/highlight/detail?id=2493177805","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493177805?lang=zh_cn&edition=full","pubTime":"2024-12-24 14:37","pubTimestamp":1735022264,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺和诺德公司日前宣布，美国FDA已批准Alhemo皮下注射剂作为一种每日一次的预防性治疗，用于预防或减少12岁及以上血友病A或B成人和儿童患者的出血频率。基于这一人群中未满足的医疗需求，以及2期临床试验的结果，FDA曾授予Alhemo治疗伴抑制物血友病B患者的突破性疗法认定。Alhemo治疗组的中位ABR为零，而未接受预防治疗患者的中位ABR为9.8。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228903.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺和诺德(NVO.US)Alhemo皮下注射剂获FDA批准 预防或减少12岁及以上血友病患者出血频率","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1093756325.SGD","LU1093756168.USD","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","BK4599","BK4588","IE00BZ1G4Q59.USD","NVO"],"gpt_icon":1},{"id":"2493778678","title":"千亿大佬被逼到墙角","url":"https://stock-news.laohu8.com/highlight/detail?id=2493778678","media":"CHC医疗传媒","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493778678?lang=zh_cn&edition=full","pubTime":"2024-12-24 14:30","pubTimestamp":1735021818,"startTime":"0","endTime":"0","summary":"REDEFINE-1研究结果一经公布，诺和诺德当日盘前最高跌幅一度达到28%，最终收报85美元美股，收跌17.83%，单日市值蒸发超过821亿美元。诺和诺德历经这一波折，或将使得全球减重药物市场竞争天平倾斜。诺和诺德的后手，真正降维打击的药物是Amycretin。目前已经大量MNC入局口服减重药物赛道，除了上述提到的诺和诺德、礼来和辉瑞，还有罗氏、阿斯利康、默沙东等，同时国内Biotech也因此受益囊获了大额BD，包括诚益生物、翰森制药等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224143215a206c7ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224143215a206c7ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PFE","IE00BZ1G4Q59.USD","SG9999003800.SGD","BK4533","LU1093756325.SGD","LU1057294990.SGD","IE00B19Z3581.USD","LU0289739699.SGD","BK4588","LU1066053197.SGD","IE00B19Z3B42.SGD","LU0225284248.USD","SG9999002224.SGD","LU0456855351.SGD","LU1894683348.USD","BK4599","IE0002270589.USD","LU0058720904.USD","BK4592","LU1894683264.USD","BK4550","SG9999002232.USD","BK4007","IE000M9KFDE8.USD","IE00BKVL7J92.USD","LU0985481810.HKD","LU1066051498.USD","SG9999011175.SGD","BK4581","BK4532","LU0154236417.USD","LU0234572021.USD","BK4568","LU0122379950.USD","BK4585","LU0306806265.USD","LU0225771236.USD","SGXZ57979304.SGD","LU0868494617.USD","BK4534","LU1883839398.USD","LU0321505439.SGD","SG9999013999.USD","LU0321505868.SGD","SG9999001176.USD","IE00BLSP4452.SGD","LU1093756168.USD","IE00BLSP4239.USD","NVO","LU1023059063.AUD"],"gpt_icon":1},{"id":"2493746721","title":"速递 | FDA最终决定结束礼来的替尔泊肽短缺问题，诺和诺德司美格鲁肽将成为下一个","url":"https://stock-news.laohu8.com/highlight/detail?id=2493746721","media":"GLP1减重宝典","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493746721?lang=zh_cn&edition=full","pubTime":"2024-12-24 11:26","pubTimestamp":1735010779,"startTime":"0","endTime":"0","summary":"整理 | GLP1减重宝典内容团队12月20日，美国食品药品管理局最终决定结束礼来公司  重磅 GLP-1 产品替尔泊肽的药品短缺问题。此前，复合药房提起的诉讼迫使 FDA 宣布审查其 10 月份的原始决定。代表山寨制造商的贸易集团表示，他们不同意 FDA 的决定。Hims 还试图向 FDA 呼吁，短缺问题尚未结束，提交了一份调查，调查对象是今年 9 月至 11 月报告出现短缺的药品分销商。Allurion 表示，它将继续提供复方司美格鲁肽以及礼来和诺和诺德的品牌产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224122051ab8fb719&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224122051ab8fb719&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0256863811.USD","SG9999015986.USD","LU2602419157.SGD","LU1551013425.SGD","BK4581","LU2324357040.USD","LU0882574055.USD","GB00BDT5M118.USD","IE0002141913.USD","IE00BKVL7J92.USD","LU0823416689.USD","LU1868836591.USD","LU0471298777.SGD","LU2237438978.USD","LU0354030511.USD","LU0122379950.USD","LU2265009873.SGD","SGXZ31699556.SGD","LU0106261372.USD","IE00BZ1G4Q59.USD","SG9999013999.USD","SG9999017495.SGD","LU0820561818.USD","LU0096364046.USD","LU0097036916.USD","LU2491050154.USD","IE0004445239.USD","LU0079474960.USD","BK4599","LU0708995401.HKD","IE00BK4W5L77.USD","SGXZ51526630.SGD","LU1366192091.USD","LU1989771016.USD","IE00B4R5TH58.HKD","IE0009355771.USD","LU1814569148.SGD","LU2361044949.HKD","NVO","LU0417517546.SGD","LU0943347566.SGD","LU1551013342.USD","BK4516","LU0882574139.USD","LLY","LU0672654240.SGD","LU2211815571.USD","LU2237443622.USD","LU1280957306.USD","LU0094547139.USD"],"gpt_icon":1},{"id":"2493741816","title":"减肥药巨头，市值蒸发625亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493741816","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493741816?lang=zh_cn&edition=full","pubTime":"2024-12-24 09:30","pubTimestamp":1735003829,"startTime":"0","endTime":"0","summary":"近日，减肥药巨头诺和诺德股价大跌约18%，市值蒸发625亿美元，约合4600亿元人民币。其市值急剧下跌的主要原因是该公司公布的减肥药物CagriSema临床数据未能达到市场预期，引发了投资者的广泛担忧。CagriSema的试验结果不及预期，不仅影响了诺和诺德的股价，也可能改变其在激烈竞争的减肥药市场中的定位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224093155a2062c37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241224093155a2062c37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","NVO","IE00BZ1G4Q59.USD","LU1093756325.SGD","BK4532","BK4585","LU0154236417.USD","LU1093756168.USD","BK4599","IE00BKVL7J92.USD","BK4007"],"gpt_icon":1},{"id":"2493745117","title":"FDA批准Hikma仿制诺和诺德(NVO.US)糖尿病药物Victoza","url":"https://stock-news.laohu8.com/highlight/detail?id=2493745117","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493745117?lang=zh_cn&edition=full","pubTime":"2024-12-24 08:34","pubTimestamp":1735000471,"startTime":"0","endTime":"0","summary":"智通财经获悉，美国食品和药物管理局周一批准了Hikma仿制诺和诺德糖尿病药物Victoza，为该药物的另一种仿制药在美国上市扫清了道路。Hikma的品牌仿制药将与Teva制药公司竞争，Teva制药公司今年早些时候在美国推出了Victoza的授权仿制药。今年6月，FDA暂时批准了这种药物。糖尿病药物Victoza是第一代GLP-1，这类治疗已经看到了压倒性的需求。该机构指出，Victoza品牌目前供不应求。由Teva生产的Victoza授权仿制药并不短缺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228770.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1093756325.SGD","LU1093756168.USD","BK4532","IE00BKVL7J92.USD","LU0154236417.USD","BK4007","BK4599","BK4588","IE00BZ1G4Q59.USD","NVO"],"gpt_icon":1},{"id":"2493579503","title":"更新版 1-更新 1-美国 FDA 批准 Hikma 公司生产诺和诺德糖尿病药物 Victoza 的仿制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2493579503","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493579503?lang=zh_cn&edition=full","pubTime":"2024-12-24 01:53","pubTimestamp":1734976398,"startTime":"0","endTime":"0","summary":"     路透12月23日 - 美国食品和药物管理局周一批准了Hikma Pharmaceuticals  的诺和诺德糖尿病药物  Victoza的仿制药，为该药物在美国的上市扫清了道路。Hikma 公司周一表示，\"很高兴获得 FDA 批准推出这一重要药物，并为依赖该药物的患者提供更广泛的治疗途径和更高的经济承受能力\"。Hikma 的仿制药已于 6 月获得美国食品及药物管理局的初步批准。糖尿病药物 Victoza 或利拉鲁肽是第一代 GLP-1，是一种需求量巨大的治疗药物。该机构表示，它会优先审查短缺药物的仿制药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","SGXZ81514606.USD","IE00BZ1G4Q59.USD","LU0820561909.HKD","LU2106854487.HKD","IE00B2B36J28.USD","BK4585","LU0471298777.SGD","LU2211815571.USD","LU1267930730.SGD","SG9999014880.SGD","IE00B1BXHZ80.USD","SG9999014914.USD","NVO","LU1035775433.USD","LU1868837136.USD","LU2023250504.SGD","SGXZ31699556.SGD","SG9999001176.SGD","LU1868837300.USD","LU0096364046.USD","LLY","LU0640476718.USD","LU1868836757.USD","LU0820561818.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","SG9999018857.SGD","BK4516","SG9999015986.USD","IE00BJLML261.HKD","LU0456855351.SGD","LU0689472784.USD","LU1623119135.USD","LU2237443622.USD","LU1551013425.SGD","LU0114720955.EUR","LU0354030438.USD","LU2237438978.USD","SG9999013999.USD","LU1280957306.USD","LU2361044949.HKD","LU0097036916.USD","LU2361044865.SGD","LU1989771016.USD","IE0002141913.USD","BK4007","BK4532","LU2237443465.HKD","LU2265009873.SGD"],"gpt_icon":1},{"id":"2493879793","title":"欧洲股市小幅走高 受益于诺和诺德强势反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2493879793","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493879793?lang=zh_cn&edition=full","pubTime":"2024-12-24 01:06","pubTimestamp":1734973576,"startTime":"0","endTime":"0","summary":"欧洲股市小幅走高，受丹麦制药商诺和诺德股价反弹提振，投资者继续关注美国利率前景对欧洲的影响。斯托克欧洲600指数收涨0.1%。医疗保健股跑赢，得益于诺和诺德从2023年8月以来的低点回升。该基准股指年迄今上涨约5%，远远落后于标普500指数同期24%的涨幅。彭博调查显示，欧元区经济明年的回升势头将低于此前预期。尽管回报不温不火，但一些市场观察人士还是看到了欧洲市场的复苏迹象，尤其是考虑到欧洲股票的低估值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122401085295eade22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024122401085295eade22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4532","BK4588","NVO","BK4007","IE00BKVL7J92.USD","BK4599","LU1093756325.SGD","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2493761531","title":"美股异动 | 诺和诺德(NVO.US)反弹超4% 此前一个交易日大跌17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2493761531","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493761531?lang=zh_cn&edition=full","pubTime":"2024-12-23 23:13","pubTimestamp":1734966785,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，诺和诺德(NVO.US)反弹超4%，此前一个交易日大跌17%，现报88.44美元。消息面上，诺和诺德上周五表示，新一代实验性减肥药CagriSema在一项后期试验中帮助超重患者减轻了22.7%的体重，低于预期的25%。该候选药物的减肥效果不及预期，对这家丹麦制药商造成了打击，该公司希望推出一款比礼来(LLY.US)的Zepbound更有效的药物，以接替其广受欢迎的Wegovy。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1228725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LU1093756168.USD","IE00BKVL7J92.USD","BK4532","LU1093756325.SGD","LU0154236417.USD","NVO","BK4007","BK4588","BK4599","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2493654757","title":"【诺和诺德反弹涨超4%】诺和诺德反弹涨超4%，分析师指该公司减肥药仍最有效。","url":"https://stock-news.laohu8.com/highlight/detail?id=2493654757","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493654757?lang=zh_cn&edition=full","pubTime":"2024-12-23 22:34","pubTimestamp":1734964444,"startTime":"0","endTime":"0","summary":"诺和诺德反弹涨超4%，分析师指该公司减肥药仍最有效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2024/12/23223446725528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4585","BK4532","BK4588","NVO","BK4007","IE00BKVL7J92.USD","BK4599","LU1093756325.SGD","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2493765112","title":"BMO Capital下调诺和诺德目标价至105美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493765112","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493765112?lang=zh_cn&edition=full","pubTime":"2024-12-23 22:24","pubTimestamp":1734963872,"startTime":"0","endTime":"0","summary":"格隆汇12月23日｜BMO Capital：将诺和诺德的目标价从156美元下调至105美元，维持“跑赢大市”评级。(格隆汇)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223222439ab8e3c78&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":"d0a97241abcd465706360c8d5bde719d","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223222439ab8e3c78&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BMO"],"gpt_icon":0},{"id":"2493503527","title":"加拿大蒙特利尔银行：维持Novo Nordisk评级，由优于大市调整至优于大市评级，","url":"https://stock-news.laohu8.com/highlight/detail?id=2493503527","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493503527?lang=zh_cn&edition=full","pubTime":"2024-12-23 21:21","pubTimestamp":1734960066,"startTime":"0","endTime":"0","summary":"加拿大蒙特利尔银行：维持Novo Nordisk(NVO.US)评级，由优于大市调整至优于大市评级,目标价由156.00美元调整至105.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223213256ab8e21a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223213256ab8e21a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BMO","NVO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.1911},{"period":"1month","weight":-0.1684},{"period":"3month","weight":-0.3118},{"period":"6month","weight":-0.3953},{"period":"1year","weight":-0.1494},{"period":"ytd","weight":-0.1554}],"compareEarnings":[{"period":"1week","weight":-0.0049},{"period":"1month","weight":0.0097},{"period":"3month","weight":0.0548},{"period":"6month","weight":0.1005},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.2651}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.016402},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.005498},{"month":8,"riseRate":0.522727,"avgChangeRate":0.001751},{"month":9,"riseRate":0.568182,"avgChangeRate":-0.002657},{"month":10,"riseRate":0.5,"avgChangeRate":-0.002241},{"month":11,"riseRate":0.613636,"avgChangeRate":0.027229},{"month":12,"riseRate":0.727273,"avgChangeRate":0.049447}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}